Нажмите на эту строку чтобы перейти к Новостям сайта "Русский врач"

Перейти
на сайт
журнала
"Врач"
Перейти на сайт журнала "Медицинская сестра"
Перейти на сайт журнала "Фармация"
Перейти на сайт журнала "Молекулярная медицина"
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
Журнал включен в российские и международные библиотечные и реферативные базы данных

ВАК (Россия)
РИНЦ (Россия)
Эко-Вектор (Россия)

"OMIX" TECHNOLOGIES: BIOCHEMICAL FEATURES OF ACTION NEURO- AND TISSUE-SPECIFIC MARKERS (REVIEW)

DOI: https://doi.org/10.29296/25877313-2023-10-04
Issue: 
10
Year: 
2023

E.A. Teplyashina
Ph.D. (Biol.), Associate Professor,
Department of Biological Chemistry with a Course in Medical, Pharmaceutical and Toxicological Chemistry,
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky
of the Ministry of Health of the Russian Federation (Krasnoyarsk, Russia)
E-mail: elenateplyashina@mail.ru
N.A. Malinovskaya
Dr.Sc. (Med.), Head of the Department of Biological Chemistry with a Course in Medical, Pharmaceutical and Toxicological Chemistry,
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky
of the Ministry of Health of the Russian Federation (Krasnoyarsk, Russia)
E-mail: malinovskaya-na@mail.ru
L.B. Shadrina
Assistant, Department of Biological Chemistry with a Course in Medical, Pharmaceutical and Toxicological Chemistry,
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky
of the Ministry of Health of the Russian Federation (Krasnoyarsk, Russia)
E-mail: shaliu@mail.ru

The article presents the results of research on modern analytical technologies, which are becoming more important. It is shown that an actively devel-oping approach to early diagnosis of diseases is metabolomics, which studies the biochemical transformations of molecules in the cells of the body. Metabolomic studies based on nuclear magnetic resonance spectroscopy and mass spectrometry open up many opportunities for studying the com-plete metabolomic profile and especially its disorders resulting from adverse environmental factors or gene expression transformation (epigenetics). It is proved that the most common research methods in the framework of modern metabolomics are considered to be metabolic fingerprinting and metabolic profiling. The large possibilities of metabolomic profiling allow us to solve a significant number of fundamental and clinical problems. Fundamental and clinical scientific data have demonstrated the feasibility of a multilateral study of the genesis and course of neurodegenerative disor-ders and cardiovascular diseases at the molecular level. Violation of metabolic pathways in certain organs and tissues can lead to significant changes in the composition of circulating peripheral blood metabolites or brain neurometabolites. Metabolism covers a wide range of biochemical reactions of the body and a diverse set of metabolites, therefore, pathological factors are able to change the metabolic profile of the body at different levels. Analysis of domestic and foreign literature has shown that quantitative determination of lipids in biological samples (lipidomics) is considered equally important in metabolic profiling. This opens up great opportunities for the study of metabolic transformations of lipid molecules, as well as lipid-dependent mechanisms, which is extremely important for the study of neurodegenerative, neurological and neuropsychiatric disorders, since, depend-ing on the associated biochemical pathways of the disease, lipids serve as potential marker molecules of these disorders and can be regarded as necessary diagnostic techniques. The conclusion is formulated about the importance of studying metabolic disorders, a more detailed understanding of the pathogenetic mechanisms of the occurrence of diseases at the molecular level, the search for new marker molecules and additional factors leading to pathological conditions of the body.

Keywords: 
metabolomics
lipidomics
biomarkers
neuromarkers.

References: 
  1. 1. Rutledge J., Oh H., Wyss-Coray T. Measuring biological age using omics data. Nature Reviews Genet. 2022; 23(12): 715–727.
  2. 2. Patti G.J., Yanes O., Siuzdak G. Metabolomics: the apogee of the omic triology. Nature Reviews Molecular Cell Biology. 2012; 13: 4: 263–269.
  3. 3. Au A., Cheng K.-K., Wei L.K. Metabolomics, lipidomics and pharmacometabolomics of human hypertension. Advances in experimental Medicine and Biology. 2016; 956: 599–613.
  4. 4. Boccard J., Gonzalez-Ruiz V., Codesido S., Rudaz S. Mass spectrometry metabolomic data handling for biomarker discov-ery. Proteomic and Metabolomic Approaches to Biomarker Discovery. 2020; 369–388.
  5. 5. Fiehn O. Metabolomics by gas chromatography-mass spec-trometry: Combined targeted and untargeted profiling. Curr. Protoc. Mol. Biol. 2016; 114(30): 1–30.
  6. 6. Amoresano A., Pucci P. Mass spectrometry in metabolomics. Metabolomics Perspective. 2022; 109–147.
  7. 7. Ortiz C., Carlen M., Meletis K. Spatial Trascriptomic: Molecu-lar Maps of the Mammalian Brain. Annual Review of Neuro-science. 2021; 44: 547–562.
  8. 8. Willsey H.R., Willsey A.J., Wang B., State M.W. Genomics, convergent neuroscience and progress in understanding autism spectrum disorder. Nat Rev Neurosci. 2022; 23(6): 323–341.
  9. 9. Коробкова Е.О., Кожевникова М.В., Ильгисонис И.С. и др. Метаболомное профилирование больных с метаболическим синдромом. Кардиология. 2020; 60(3): 37–43. (Korobkova E.O., Kozhevnikova M.V., Il'gisonis I.S. i dr. Metabolomnoe profilirovanie bol'nyx s metabolicheskim sindromom. Kardiologiya. 2020; 60(3): 37–43).
  10. 10. Armand E.J., Li J., Xie F., Luo C., Mukamel E. Single-Cell Sequencing of Brain Cell Transcriptomes. Neuron. 2020; 109: 6: 11–26.
  11. 11. Bai B., Wang X., Li Y., Chen P.-C., Yu K., Dey K.K. Deep Mul-tilayer Brain Proteomics Identifies Molecular Networks in Alzheimer's Disease Progression. J. Nutr. 2020; 105(6): 9759–991.
  12. 12. Sinclair E., Trivedi D.K., Sarkar D., WaltonDoyle C., Milne J., Rijs A.M., A de Bie R. M., Goodacre R., Silverdale M., Barran P. Metabolomics of sebum reveals lipid dysregulation in Park-inson's disease. Int. J. Clin. Exp. Med. 2021; 12(1): 1592.
  13. 13. Yang L., Lv P., Ai W., Li L., Shen S., Nie H., Shan Y., Bai Y., Huang Y., Liu H. Lipidomic analysis of plasma in patients with lacunar infarction using normal-phase/reversed-phase two-dimensional liquid chromatography–quadrupole time-of-flight mass spectrometry. Anal. Bioanal. Chem. 2017; 409: 3211–3222.
  14. 14. Purroy F., Cambray S., Mauri-Capdevila G., Jove M., Sana-huja J., Farre J., Benabdelhak I., Molina-Seguin J., Colàs-Campàs L., Begue R. Metabolomics predicts neuroimaging characteristics of transient ischemic attack patients. EBioMedi-cine. 2016; 14: 131–138.
  15. 15. Poupore N., Chosed R., Arce S., Rainer R., Goodwin R.L. Metabolomic Profiles of Men and Women Ischemic Stroke Pa-tients. Talanta. 2021; 11(10): 1786.
  16. 16. Hook V., Lietz C., Podvin S., Cajka T., Fiehn O. Diversity of Neuropeptide Cell-Cell Signaling Molecules Generated by Proteolytic Processing Revealed by Neuropeptidomics Mass Spectrometry. J Am Soc Mass Spectrom. 2018; 29(5): 807–816.
  17. 17. Close J.L., Long B.R., Zeng H. Spatially resolved tran-scriptomic in neuroscience. Front. Mol. Neurosci. 2021; 18(1): 23–25.
  18. 18. Горина Я.В., Комлева Ю.К., Лопатина О.Л., Черных А.И., Салмина А.Б. Влияние инсулинорезистентности на нару-шение метаболизма глюкозы в миндалине головного моз-га при экспериментальной болезни Альцгеймера. Бюлле-тень сибирской медицины. 2017; 16(4): 106–115. (Gorina Ja.V., Komleva Ju.K., Lopatina O.L., Chernyh A.I., Salmina A.B. Vlijanie insulinorezistentnosti na narushenie metabo-lizma gljukozy v mindaline golovnogo mozga pri jeksperi-mental'noj bolezni Al'cgejmera. Bjulleten' sibirskoj mediciny. 2017; 16(4): 106–115).
  19. 19. Комлева Ю.К., Горина Я.В., Черных А.И., Лопатина О.Л., Шабалова А.А., Труфанова Л.В., Оловянникова Р.Я., Енд-ржеевская-Шурыгина В.Ю., Салмина А.Б. Особенности пролиферации и миграции клеток головного мозга при когнитивном тренинге животных с экспериментальной болезнью Альцгеймера. Сибирское медицинское обоз-рение. 2016; 6: 1–5. (Komleva Ju.K., Gorina Ja.V., Chernyh A.I., Lopatina O.L., Shabalova A.A., Trufanova L.V., Olovjannikova R.Ja., Endrzheevskaja-Shurygina V.Ju., Sal-mina A.B. Osobennosti proliferacii i migracii kletok golov-nogo mozga pri kognitivnom treninge zhivotnyh s jeks-perimental'noj bolezn'ju Al'cgejmera. Sibirskoe medicinskoe obozrenie. 2016; 6: 1–5).
  20. 20. Chen Q., Zhou T., Yuan J., Xiong X., Liu X., Qiu Z., Hu L., H. Lu, He Q., Liu C., Yang Q. Metabolomics profiling to charac-terize cerebral ischemia-reperfusion injury in mice. Front Pharmacol. 2023; 14: 1091616